Craig-Hallum Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $62
Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc. ETON | 0.00 |
Craig-Hallum analyst Chase Knickerbocker maintains Eton Pharmaceuticals (NASDAQ:
ETON) with a Buy and raises the price target from $40 to $62.
